{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:19Z","timestamp":1793773819279,"version":"4.6.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.1080\/14737140.2023.2171994","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T16:17:23Z","timestamp":1675268243000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M Lia","family":"Palomba","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik R","family":"Patel","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Nahas","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Beygi","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J","family":"Hatswell","sequence":"additional","affiliation":[{"name":"Delta Hat, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5398","authenticated-orcid":false,"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[{"name":"RainCity Analytics, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-8030","authenticated-orcid":false,"given":"Eve H.","family":"Limbrick-Oldfield","sequence":"additional","affiliation":[{"name":"RainCity Analytics, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W","family":"Wade","sequence":"additional","affiliation":[{"name":"Wade Outcomes Research and Consulting, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markqayne D","family":"Ray","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Owen","sequence":"additional","affiliation":[{"name":"Delta Hat, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S","family":"Neelapu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[{"name":"Cancer Research UK Barts Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"The University of Manchester and Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Bobillo","sequence":"additional","affiliation":[{"name":"Vall D\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278717"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1002\/hon.26_2880"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e19548"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000745"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00033-3"},{"key":"cit0010","unstructured":"Food and Drug Administration. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma: u.S. Food and Drug Administration; 2021a [2022 Sept 6th]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma"},{"key":"cit0011","unstructured":"Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma: u.S. Food and Drug Administration; 2021b [2022 Sept 6th]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma"},{"key":"cit0012","unstructured":"European Medicines Agency. New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma 2022a [2022 Sept 6th]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-therapeutic-indications-for-axicabtagene-ciloleucel"},{"key":"cit0013","unstructured":"European Medicines Agency. New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy 2022b [2022 Sept 6th]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-therapeutic-indications-for-tisagenlecleucel"},{"issue":"1","key":"cit0014","first-page":"40","volume":"136","author":"Jacobson C","year":"2020","journal-title":"Blood"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"issue":"21","key":"cit0017","first-page":"00591","volume":"8","author":"Jacobson CA","year":"2021","journal-title":"Lancet Oncol"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj149"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0442-1"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00973"},{"key":"cit0021","volume-title":"Causal Inference: what If","author":"Hern\u00e1n MARJ","year":"2020"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15199"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236345"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"cit0029","unstructured":"Summary basis for regulatory action, (2017)."},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7552"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149327"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"cit0035","unstructured":"Study of axicabtagene ciloleucel versus standard of care therapy in participants with relapsed\/refractory follicular lymphoma (ZUMA-22) (NCT05371093) [cited 2022]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05371093"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2023.2171994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T16:52:47Z","timestamp":1677689567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2023.2171994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1080\/14737140.2023.2171994"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2023.2171994","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}